Genzyme Europe B.V

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the worlds leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the worlds largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded through both in-house development and strategic acquisitions and partnerships to other disease areas such as thyroid cancer and multiple sclerosis. Driven by ...